Alder Biopharmaceuticals Inc (ALDR) : Partner Investment Management scooped up 32,986 additional shares in Alder Biopharmaceuticals Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 69,742 shares of Alder Biopharmaceuticals Inc which is valued at $2,171,068.Alder Biopharmaceuticals Inc makes up approximately 3.91% of Partner Investment Management’s portfolio.
Other Hedge Funds, Including , Polar Capital Llp added ALDR to its portfolio by purchasing 75,000 company shares during the most recent quarter which is valued at $2,334,750. Alder Biopharmaceuticals Inc makes up approx 0.04% of Polar Capital Llp’s portfolio.Senzar Asset Management reduced its stake in ALDR by selling 174,500 shares or 33.98% in the most recent quarter. The Hedge Fund company now holds 339,070 shares of ALDR which is valued at $10,555,249. Alder Biopharmaceuticals Inc makes up approx 2.10% of Senzar Asset Management’s portfolio.Pictet Asset Management Ltd boosted its stake in ALDR in the latest quarter, The investment management firm added 353,254 additional shares and now holds a total of 433,054 shares of Alder Biopharmaceuticals Inc which is valued at $13,480,971. Alder Biopharmaceuticals Inc makes up approx 0.05% of Pictet Asset Management Ltd’s portfolio.Rhumbline Advisers boosted its stake in ALDR in the latest quarter, The investment management firm added 19,950 additional shares and now holds a total of 44,025 shares of Alder Biopharmaceuticals Inc which is valued at $1,370,498. Nine Chapters Capital Management sold out all of its stake in ALDR during the most recent quarter. The investment firm sold 7,400 shares of ALDR which is valued $225,108.
Alder Biopharmaceuticals Inc closed down -0.43 points or -1.30% at $32.54 with 3,97,238 shares getting traded on Thursday. Post opening the session at $32.96, the shares hit an intraday low of $32.045 and an intraday high of $33.23 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
On the company’s financial health, Alder Biopharmaceuticals Inc reported $-0.76 EPS for the quarter, missing the analyst consensus estimate by $ -0.04 based on the information available during the earnings call on Apr 28, 2016. Analyst had a consensus of $-0.72.Analysts expectations of $ .14.During the same quarter in the previous year, the company posted $-0.40 EPS.
Alder Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company discovers develops and seeks to commercialize therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. The Company has developed an antibody platform designed to select antibodies that have the potential to maximize efficacy as well as speed of onset and durability of therapeutic response. The Company’s pipeline includes ALD403 Clazakizumab and ALD1613. ALD403 is the Company’s monoclonal antibody targeted to calcitonin gene-related peptide (CGRP) for migraine prevention. Clazakizumab is a monoclonal antibody that inhibits the pro-inflammatory cytokine interleukin-6 (IL-6) and is in development for both rheumatoid arthritis (RA) and psoriatic arthritis (PsA). ALD1613 is a monoclonal antibody that inhibits Adrenocorticotropic Hormone (ACTH) and is being developed for the treatment of Cushing’s disease.